Annovis R&D Costs Surge as Alzheimer’s Trial Reaches Full Enrollment
MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) more than doubled second-quarter research spending as its pivotal Phase 3 Alzheimer’s disease trial reached full enrollment at 850 patients, positioning the …
Annovis R&D Costs Surge as Alzheimer’s Trial Reaches Full Enrollment Read More